Correct staging of
prostate cancer is an unmet clinical need.
Radionuclide targeting of prostate-specific membrane
antigen (PSMA) with 111In-labeled
capromab pendetide (
ProstaScint) is a clinical option for
prostate cancer staging. We propose the use of 124I-labeled
capromab to decrease the retention of radioactivity in healthy organs (due to the non-residualizing properties of the radiolabel). The use of 124I as a label should increase imaging sensitivity due to the advantages of PET as an imaging modality.
Capromab targets the intracellular domain of PSMA; accumulation of radioactivity in the
tumor should not depend on internalization of the
antigen/antibody complex.
Capromab was iodinated, and its targeting properties were compared with
indium labeled counterpart in LNCaP xenografts in dual
isotope mode. PSMA-negative xenografts (PC3) were used as a negative control. Radioiodinated
capromab bound to PSMA specifically. Biodistribution of 125I/111In-
capromab showed a more rapid clearance of
iodine radioactivity from liver, spleen, kidneys, bones, colon tissue, as well as
tumors. Maximum
tumor uptake (13±8% ID/g for
iodine and 29±9% ID/g for
indium) and
tumor-to-non-
tumor ratios for both agents were measured 5 days post-injection (pi). High
tumor accumulation and low uptake of radioactivity in normal organs were confirmed using microPET/CT 5 days pi of 124I-capromab.